The UPCI Cancer Immunology Program (CIP) is a basic and preclinical research program, with members recruited from the large group of immunologists at the University of Pittsburgh and Carnegie Mellon University. The majority of Program members conduct research directly related to tumor immunology, and the rest are immunologists recruited into the Program for their expertise and cutting-edge research in related areas of organ rejection, infectious disease, and autoimmunity that can contribute to the understanding of immune mechanisms important for tumor-specific immunity.
Program members interact scientifically in several major research areas:
The scientific goals of the CIP are to:
- Elucidate the basic mechanisms of the initiation and effector phases of tumor-specific immunity;
- Characterize the mechanisms of immune escape and immune exploitation; and
- Develop cancer animal models for immunoprevention or immunotherapy.
The mandate of the Program is to encourage, facilitate, and support the best research and training in cancer immunology, and to translate basic findings from the members' laboratories into the preclinical and clinical arena through active interactions with the translational disease-site UPCI programs.